The FDA has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets, from Bayer HealthCare, for the...
Oral contraception. Treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The decision to prescribe Qlaira should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Qlaira compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).
Treatment of endometriosis.